Cargando…

Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma

Transforming growth factor beta (TGFβ) and programmed death-ligand 1 (PD-L1) are often overproduced in refractory squamous cell carcinoma (SCC). We examined spatial patterns of PD-L1(+) cells in mouse and human SCCs and found that PD-L1 was primarily expressed on infiltrating leukocytes. Although co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strait, Alexander A., Woolaver, Rachel A., Hall, Spencer C., Young, Christian D., Karam, Sana D., Jimeno, Antonio, Lan, Yan, Raben, David, Wang, Jing H., Wang, Xiao-Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387430/ https://www.ncbi.nlm.nih.gov/pubmed/34433873 http://dx.doi.org/10.1038/s42003-021-02522-2

Ejemplares similares

Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors
por: John, Jessy, et al.
Publicado: (2022)

Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders
por: John, Jessy, et al.
Publicado: (2023)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
por: Lim, Yoong Wearn, et al.
Publicado: (2021)

Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas
por: Bhatia, Shilpa, et al.
Publicado: (2016)

PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma
por: Zeng, Qingyu, et al.
Publicado: (2022)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Kroemer, Guido, et al.
Publicado: (2021)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

USP12 downregulation orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade
por: Yang, Zhaojuan, et al.
Publicado: (2021)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade
por: Li, Xue, et al.
Publicado: (2019)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
por: Fang, Douglas D., et al.
Publicado: (2019)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment
por: Zheng, Jun, et al.
Publicado: (2023)

Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
por: Sun, Lu, et al.
Publicado: (2023)

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
por: Wakiyama, Hiroaki, et al.
Publicado: (2022)

The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses
por: Cui, Guanglin
Publicado: (2021)

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
por: Wang, Simeng, et al.
Publicado: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Callejas-Valera, Juan L., et al.
Publicado: (2022)

Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
por: Lv, Ji, et al.
Publicado: (2019)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2021)

B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression
por: Hou, David, et al.
Publicado: (2023)

Roles of TGFβ signaling Smads in squamous cell carcinoma
por: Han, Gangwen, et al.
Publicado: (2011)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

Tumor microenvironment characterization in head and neck squamous carcinoma reveals distinct genomic alterations and clinical outcomes
por: Shi, Run, et al.
Publicado: (2020)

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer
por: Wang, Zhixiong, et al.
Publicado: (2023)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1b307uvq72tatm69pear92d0vh